CALL FOR PROPOSALS 2016

Fellowships for Italy

Via San Vito 7, 20123 Milano
email: airc.direzione-scientifica@airc.it
tel. 02/7797410
In this Call:
36 three-year fellowships
3 one-year fellowships

<table>
<thead>
<tr>
<th>Fellowships</th>
<th>Donors’ requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>23 three-year fellowships FIRC-AIRC</td>
<td>-</td>
</tr>
<tr>
<td>5 three-year fellowships “Leonino Fontana e Maria Lionello”</td>
<td>-</td>
</tr>
<tr>
<td>4 three-year fellowships “Luca Erizzo”</td>
<td>applications must have a research plan focused on pancreas or oncogenesis and metabolism</td>
</tr>
<tr>
<td>2 three-year fellowships “Pierluigi Meneghelli”</td>
<td>-</td>
</tr>
<tr>
<td>2 three-year fellowships “Angelo Nardino”</td>
<td>-</td>
</tr>
<tr>
<td>1 one-year fellowship “Jole Mentasti”</td>
<td>-</td>
</tr>
<tr>
<td>1 one-year fellowship “Fabrizio Ansuini”</td>
<td>-</td>
</tr>
<tr>
<td>1 one-year fellowship “Giovanna Farris”</td>
<td>-</td>
</tr>
</tbody>
</table>
TABLE OF CONTENTS

Foreword .............................................................................................................................................. 4
Eligibility criteria for applicants .......................................................................................................... 4
The Hosting Institution .......................................................................................................................... 5
The research plan ................................................................................................................................... 5
The review process .............................................................................................................................. 5
Funding ................................................................................................................................................ 6
Duration and Renewals ....................................................................................................................... 6
Bio-Ethical Requirements .................................................................................................................... 7
Deadlines .............................................................................................................................................. 8
Guide to proposal preparation ............................................................................................................ 10
  Applicant’s personal data ..................................................................................................................... 11
  Type of fellowship ............................................................................................................................... 11
  Head of the hosting lab ......................................................................................................................... 11
  Legal representative ............................................................................................................................. 11
  Head of the laboratory of origin .......................................................................................................... 11
  Education and training of the applicant .............................................................................................. 12
  Research and professional experience of the applicant .................................................................... 12
  Research interruptions and justifications ............................................................................................ 12
  Curriculum vitae of the applicant ....................................................................................................... 12
  Narrative biosketch ............................................................................................................................. 12
  Certificate of graduation .................................................................................................................... 12
  Publications of the applicant .............................................................................................................. 12
  Project keywords ............................................................................................................................... 14
  Research project ............................................................................................................................... 14
  Letter of acceptance of the Hosting Institution ................................................................................ 15
  Education and training of the head of the hosting lab .................................................................... 15
  Research and professional experience of the head of the hosting lab .......................................... 15
  Publications of the head of the hosting lab ..................................................................................... 15
  Bio-Ethical Requirements ................................................................................................................ 15
  Proposal PDF Draft ........................................................................................................................... 18
  Final Full Proposal Submission ........................................................................................................ 18
Template - Convenzione per l’erogazione di borse di studio finanziate dalla Fondazione Italiana per
la Ricerca sul Cancro - AIRC ................................................................................................................... 19

Keywords..............................................................................................................................................after page 22
Foreword
The Fondazione Italiana per la Ricerca sul Cancro - AIRC henceforth referred to as Foundation will award a total of 39 Fellowships in cancer research to highly qualified young graduates and/or post-doctoral fellows or equivalent who wish to broaden or acquire experience in oncological research in a cancer-focused laboratory.

Eligibility criteria for applicants
At the time of the deadline for submission, and regardless of the type of fellowship, the following eligibility criteria must be met:

- applicants must have a degree in Medicine, Biological Sciences, Pharmacy, Chemistry and Pharmaceutical Technology, Medical Statistics, Medical Biotechnologies or other scientific disciplines, provided that the focus of the proposed research plan in the application is cancer;
- the degree must be an Italian laurea magistralis, i.e. 5-6 years of undergraduate degree, or an equivalent non Italian degree (candidates who only have a “laurea breve” are not eligible), and it must have been attained after December 31, 2009. Exceptions are allowed only in case of research interruptions due to parental leave, children care, illness.

Applications from researchers who do not meet these requirements will be rejected.

Furthermore:
- mobility, i.e. the choice to carry out the research activity in an Institute located in a different place from the one of origin, will be considered a preferential title for all fellowships (only in case candidates have not been affiliated to the Hosting Institution for more than 3 months at the time of the deadline of this Call);
- fellowships are not compatible with any other continuous employment income;
- through the online application form, candidates may automatically apply to all fellowships available in this Call. We urge all applicants to apply both to Associazione Italiana Ricerca sul Cancro (AIRC) and Fondazione Fellowships for Italy. Applicants can indicate the duration of the fellowship they prefer (1-2-3 years) through the application form;
- some fellowships may have specific requirements, asked by the donors and listed on page 2 of this Call. Unless stated otherwise (i.e. “applicants must …”), please note these requirements are not mandatory but only represent a priority criterion. At the end of the review process, a final ranking of all candidates based on merit will be established. Among the candidates falling within the fundability range of this ranking, the staff of the Peer Review Office will try to establish the best possible match between the donors’ requirement(s) and an applicant (see “The review process”, below);
- applicants who have already been awarded one three-year fellowship for Italy cannot apply to this Call. Researchers cannot be supported by fellowships for more than three years total (e.g. recipients of a two-year fellowship would be eligible ONLY for a one-year fellowship) under these funding schemes;
- a maximum of two candidates with the same head of the lab of origin can apply;
- a maximum of two candidates with the same head of the Hosting lab can apply.
The Hosting Institution

For the entire duration of the fellowships applicants must operate in the Hosting Institution, i.e. a research organization (such as university, hospital or other research center), irrespective of its legal status (organized under public or private law), whose primary goal is to independently conduct non-economic biomedical research and to disseminate its results. Possible revenues coming from non-economic research activity must be completely reinvested in the non-economic research activities. Where the Hosting Institution also pursues economic activities, the financing, the costs and the revenues of those economic activities must be accounted for separately. Shareholders, members or other individuals that can exert a decisive influence upon the Hosting Institution cannot enjoy a preferential access to the intellectual property of the results generated by the non-economic research activity. Any change occurring in the relationship between the fellow and the Hosting Institution (e.g. termination, leave of absence, etc.) or in the Hosting Institution legal entity or organization (e.g. changes in Institution name, merging, Legal representative turn-over, changes in addresses) must be promptly notified to the Foundation.

Hosting Institutions must assure optimal working conditions to the fellows: in addition to providing facilities, equipment, and infrastructure, the Hosting Institution, and especially the head of the hosting lab, are expected to offer adequate training resources and cover expenses to travel to conferences and meetings when they are deemed important for the training and education of the fellow.

A letter of acceptance of the applicant by the head of the hosting lab must be included in the application, describing all resources and training opportunities available. The head of the hosting lab is expected to supervise the work of the fellow, and provide training and mentoring.

The research plan

Applications must include a detailed research plan, agreed with the head of the hosting lab, with a clear focus on cancer. The same research project cannot be presented by two or more applicants within the 2016 under these funding schemes.

The review process

All applications undergo an initial administrative review by the staff of the Peer Review Office for compliance with guidelines and eligibility; those that do not conform will be triaged out. Applications that meet the eligibility requirements undergo a peer review process that ensures a fair, independent and expert evaluation of their scientific merit and competitiveness.

All applications will be evaluated by recognized Italian scientists, members of Comitato Tecnico Scientifico. Three reviewers will assess independently each application. Reviewer assignments are made in compliance with conflict of interest rules to ensure a review free from inappropriate influence. The policy on Conflict of Interest is available here: https://www.direzionescientifica.airc.it/Policies/Default.aspx

When accepting to evaluate an application, reviewers agree that they will maintain the confidentiality of the application and associated materials they have received.

The following review criteria will be used to evaluate applications:

- Quality of the Hosting laboratory and Institution

  Reviewers will evaluate the quality of the Hosting Institution (laboratories, facilities, training potential also in complementary skills) as well as the competence of the head of the hosting laboratory (in terms of expertise in the field, track record, international standing and ability to provide mentoring).
• **Curriculum vitae of the applicant**  
  Reviewers will evaluate the applicant’s education/transcripts, track record and expertise.

• **Research proposal**  
  The research project will be judged based on its relevance to cancer, innovation, feasibility, and overall scientific/technological quality.

When all evaluations have been submitted, reviewers are invited to read the critiques of the other two reviewers who evaluated the same applications and to make additional comments, if needed. For each application, the scores received from all reviewers will be averaged to generate the application’s global score, which will be used to rank the applications. The selection will be exclusively based on this ranking and, subsequently, on the eligibility of each applicant to the specific requirements of each fellowship (fellowships may have requirements, generally asked by donors, in terms of duration, topic of research, region of provenance of the applicants, region where the research must be carried out; when present, such requirements are indicated on page 2 of the Call).

Provided that funds are available, AIRC reserves the right to increase the number of fellowships to be awarded and/or their duration, in case the requests of applicants considered meritorious of funding exceeds the number and types of fellowships listed on page 2. At the end of the review process, on the date indicated in the Deadlines table, all candidates will be notified of the result of their application with a communication from the Foundation that will include the reviewers’ comments. The identity of the reviewers will not be disclosed. The decision cannot be appealed.

**Funding**

The gross amount of each fellowship is € 25,000 per year. The Foundation will transfer the fellowship funds to the Hosting Institution, which will then pay the fellow directly. Please note that **it will not be possible to grant a fellowship if an agreement regulating the administrative responsibilities and management of the fellowship award is not signed between the Hosting Institution and the Foundation.** A template of the agreement is included at the end of this Call.

Signing the application, the Legal Representative of the Hosting Institution accepts the terms and conditions of the attached agreement. At the end of the fellowship appointment, Hosting Institutions may be requested to provide a financial reconciliation statement.

Please note that depending on the legislation and the rules applied by the Hosting Institution, fellowships can be regulated by different types of contracts, so they may not be tax-exempt, in which case revenue taxes or employee social security contributions will be deducted. For instance, Universities may be able to offer a tax-exempt fellowship, while this option may not be available in non-academic institutions.

The amount granted is intended to cover the salary of the fellow only: deductions by the Hosting Institution for indirect costs or overheads are not allowed.

**Duration and Renewals**

Fellowships have a duration of either one or three years (see page 2). In a specific section of the application form it will be possible to indicate the preference. Independently of the duration, all fellowships will start on January 1st 2017 provided that the agreement between the Foundation and the Hosting Institution has been signed. Renewals for two and three-year fellowships must be submitted yearly (see Deadlines), through the appropriate online forms. At the end of the funding period, a final scientific report is required for all fellowships (see Deadlines).
**Bio-Ethical Requirements**

For studies involving human subjects, human biological samples or for animal experimentation, the approval of the competent authorities is mandatory and must be submitted with the full application. The fellowship will not be awarded in the absence of the necessary authorizations. If the approval from the competent authorities is not available by the submission deadline, the applicant must obtain it by November 15th 2016 if possible, or before the start of the fellowship; please upload it as PDF file in the “Personal Area” or send it by e-mail (airc.direzione-scientifica@airc.it).
Deadlines

**Deadlines are strictly enforced:** applications will not be accepted beyond the relevant deadlines.

**Deadlines for applications (by 5 PM, Central Europe Time, of the indicated dates)**

<table>
<thead>
<tr>
<th>Applications</th>
<th>publication of call and release of online application forms</th>
<th>May 17 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>electronic submission deadline</td>
<td></td>
<td>June 27, 2016</td>
</tr>
<tr>
<td>paper submission (postmark) deadline (*)</td>
<td></td>
<td>July 7, 2016</td>
</tr>
<tr>
<td>notification of results</td>
<td></td>
<td>November 30, 2016</td>
</tr>
<tr>
<td>start of fellowship</td>
<td></td>
<td>January 1, 2017</td>
</tr>
</tbody>
</table>

(*) For paper submissions: please print and sign in the appropriate spaces:

- Title Page (listing the applicant’s data, Hosting Institution etc.)
- Abstract
- Bio-Ethical requirements page, stamped and signed by the candidate

Please note that in the Title page two signatures are required: the Legal representative’s and the fellow’s. Should it be difficult to obtain both signatures in the same page (e.g. in case the fellow is not already in the Hosting Institution), it is possible to send separately two paper copies of this page, one with the signature of the fellow, and one with the signature of the Legal representative.

*** Paper documentation marked with “draft” is not valid. Please print the requested pages only after completion of the submission online ***

Send these pages to:

**Fondazione Italiana per la Ricerca sul Cancro - AIRC**
Peer Review Office
via San Vito 7
20123 Milano

If these documents are not sent by the indicated deadline, or if the Foundation does not receive them, applications will not be sent out for review.
Deadlines for renewals and final report (by 5 PM, Central European Time, of the indicated dates):

### One-year fellowships

<table>
<thead>
<tr>
<th></th>
<th>Online form release date</th>
<th>Electronic submission deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final report</td>
<td>November 9, 2017</td>
<td>December 12, 2017</td>
</tr>
</tbody>
</table>

### Three-year fellowships

<table>
<thead>
<tr>
<th>Renewal for 2nd year of funding</th>
<th>Online form release date</th>
<th>Electronic submission deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>April 24, 2017</td>
<td>June 6, 2017</td>
</tr>
<tr>
<td>Renewal for 3rd year of funding</td>
<td>April 24, 2018</td>
<td>June 5, 2018</td>
</tr>
<tr>
<td>Final report</td>
<td>November 9, 2019</td>
<td>December 11, 2019</td>
</tr>
</tbody>
</table>

The deadlines for renewal requests and final reports may be subjected to changes. In this case, fellows will be notified of the new deadlines by e-mail.
Guide to proposal preparation

General information
Candidates must apply via the AIRC online portal after setting up a personal account: go to www.airc.it; click on “Area Ricercatori”; click on “Register (for applicants only)” and provide the requested information, including the Italian tax code (codice fiscale), if applicable. Make sure to indicate an e-mail address and phone number where you can be easily reached during all stages of the peer review process; if possible, please include a mobile phone number. The registration will be confirmed by e-mail and a username and password will be provided. You must login to access the application form.

To launch the application form for the first time, click on “Calls”, select “Fellowships”, then click on “Apply” in the Fellowships for Italy 2016 section. In the next window, click on “Access the application form”. To access the application in progress, click on “Submissions” and then click on “Access the application form”.

Below you will find a list of the general features of our online system:

- all forms that must be filled out are listed on the left side of the page. Click on each one of them and fill in all the mandatory fields (in bold). Make sure to click on “SAVE” after completing each form; it may be necessary to update the page of the browser to see that the information has been saved;
- the forms can be filled out at different times and the work can be interrupted/resumed at any time;
- a number of forms must be submitted as PDF files. Each file cannot exceed 2Mb. Any file exceeding such a limit will be automatically rejected by the system. Secure PDF files cannot be uploaded. Documents submitted as PDF files must be written using an A4 format, single spaced, with margins not less than 2 cm and a font not smaller than 12 point (preferably Palatino, Times, Arial). Do not exceed the page limit indicated for each section: the system will not allow the upload of a number of pages beyond the limit;
- the status of each form is shown on the left: red cross for mandatory forms that are incomplete; yellow circle for not mandatory forms; green mark for completed forms. These same symbols are used in the “Check and Submit” section;
- the “Check and Submit” section (last title in the list of forms on the left) allows applicants to:
  a. check and see whether each form has been correctly filled out; for mandatory forms that are incomplete, the information that must be provided is listed;
  b. view and print the application in its incomplete/complete state. By clicking on “Create draft” and then on “Open submission draft” you can download the PDF draft generated by the system;
  c. submit the application. Once all mandatory forms are complete, please click on “Submit”. Be aware that after clicking on “Submit” it will not be possible to make any further modifications;
- the complete proposal is automatically assembled as a whole PDF file at the end of the online procedure;

The application must be written entirely in English. Applications that do not conform to all the requirements in these instructions will be rejected.
**Applicant’s personal data**
Most fields are automatically filled out with information provided during the registration into the AIRC website; to modify the information in any of these fields, please click on the link “My personal data” at the bottom of the page and edit the information from the pop-up window.
In the “Address” field, please indicate the postal address (home or workplace) where documents related to the fellowship can be mailed to.
Please provide the ORCID identifier, if available. ORCID (Open Researcher and Contributor ID) provides a persistent digital identifier that distinguishes the applicant from every other researcher; for more information, visit the website http://orcid.org/. Although not mandatory, we encourage applicants to register into the ORCID website and then insert their ORCID identifier in the corresponding box in the application.
In the “Education (Undergraduate)” field please enter the details of the undergraduate degree obtained (i.e. the degree that formally allows one to embark on a doctorate in the country where the degree was attained; in Italy, this would be a “laurea magistralis”).
In the “Education (PhD)” field, when applicable, please indicate whether you earned a doctorate degree by checking the appropriate box at the “I obtained a PhD” question. If you do hold a PhD, please indicate: the country where you earned it; the research field; the official date it was awarded; the mark/score (write N/A if not applicable); the University.

**Type of fellowship**
In the upper part of the form: please enter the title of the research proposal; it must not exceed 120 characters, small cases, spaces included.
In the lower part of the form, please indicate the preferred duration of the fellowship, and the preferred funding body. **We urge applicants to select “BOTH” funding bodies.**

**Head of the hosting lab**
Please fill in the requested fields.

**Legal representative**
The Legal representative (Legale rappresentante) of the Hosting Institution will be responsible, along with the head of the hosting lab, of all the legal and administrative duties of the fellowship award. The information regarding the Legal representative (and the Scientific Director, if any) are provided automatically by the system based on the Hosting Institution selected in the “Head of the hosting lab” section. In case the Director of a Department within the Hosting Institution is duly authorized to sign as Legal representative of the Department, check the box “By flagging this check box you are declaring that the Director of the Department is duly authorized to sign on behalf of the Legal Representative of the Institution”. Please note that by flagging this box the PI certifies that the Director of the Department has power of attorney. Please make sure that all data are correct and up-to-date, then click on “Save”. If they aren’t, please notify the administrative office by e-mail (administrative.office@airc.it) and provide an official record (e.g. copy of Appointment Decree) as supporting documentation.

**Head of the laboratory of origin**
If there is no mobility, please click on “Same as the Head of the hosting lab”. Otherwise, please fill in the requested fields and attach a letter of presentation of the applicant by the head of the lab of origin. The letter must be in letterhead paper, dated and signed, must not exceed one page in length (approx. 500 words, font size 12), and must be uploaded as PDF file.
In case the head of the lab of origin requests the letter of recommendation not to be included in the application, please upload a statement indicating that, in order to maintain confidentiality, the letter will be sent separately to the Peer Review Office. The letter should be sent by e-mail to: airc.direzione-scientifica@airc.it by the deadline of this Call (June 27th 2016). The Peer Review Office will forward the letter to the reviewers assigned to the application.
**Education and training of the applicant**
Click on “Add new record” and list all degrees obtained (undergraduate, master’s and doctoral).

**Research and professional experience of the applicant**
Click on “Add new record” and list all positions held by the applicant after the attainment of the highest degree (e.g. PhD) indicated in the previous section; use this section to list post-doctoral trainings. **Do not leave any period unaccounted for.**

**Research interruptions and justifications**
This section should be completed in case the applicant’s research activity has been interrupted for at least 5 months due to parental leave, children care, illness or other personal issues. Click on “Add new record” and fill out the requested fields.
This section allows applicants to report prolonged periods of absence from work in the past five years that may have had a negative impact on their track record. Reviewers are instructed to take this information into account when assessing the scientific productivity of an applicant.

**Curriculum vitae of the applicant**
The *Curriculum vitae* of the applicant must not exceed the two-page length. The CV, to be uploaded as PDF file, should integrate the biographical sketch outlined in the “Education and training” and “Research and professional experience” sections, and should contain the following information:

- Name of applicant;
- Research experience: for the most relevant entries in the sections “Education and training of the applicant” and “Research and professional experience of the applicant”, please indicate the name of the supervisor and describe very briefly (two-three sentences) the main focus of the research activity carried out;
- Technical skills, competences, clinical activity (if applicable);
- Awards, participation to international meetings and courses.

**Do not list the applicant’s publications in the CV, as there is a separate, specific section for this (“Publications of the applicant”, below).**

**Narrative biosketch**
In this section applicants are invited to explain how their education and early experience in a research lab have shaped their motivation and interest in pursuing a career in cancer research. They should also describe how they will benefit from working in the selected hosting lab and why it represents the most suitable place to for their personal and professional development.
Upload the document as PDF file (maximum 1 page, approx. 500 words).

**Certificate of graduation**
Please upload a copy, in PDF format, of the degree certificate and transcripts (i.e. scores obtained in individual exams). To facilitate the work of reviewers who may not be familiar with the academic transcripts of the applicant’s country, especially if in a language different than English, please include a page with a description (or translation) of the certificate provided and of the score range (e.g. for Italian applicants uploading a certificate of *laurea magistralis*, please explain that the scores of individual exams range from 18 to 30, 30 being the best score obtainable, and that the final score or *voto di laurea* can go from 80 to 110, 110 being the best score).

**Publications of the applicant**
Applicants must provide the list of papers published in the last five years. To do so, a number of options is available; click on any that applies.
Add PubMed publications

Within this interface the system launches a PubMed search and provides a list of PubMed-recorded publications spanning from 2011 to 2016. Enter the applicant’s first and middle initials, and click on “Find”. If the applicant has published with a different last name than that used to register into the AIRC account (e.g. married vs maiden name), check the “Change surname” box, and then click on “Find”. Alternatively, search for a specific article by entering its PubMed ID in the corresponding box. Once the list of all PubMed publications has been generated, please follow these steps:

a. Select papers to be included in the application
   From the list of all PubMed publications, select the papers published by the applicant and that the applicant wants to include in the proposal by clicking on the box at the left side of each article. Pay special attention to potential homonyms. Do not include abstracts, conference papers, letters to the editor, book chapters and papers published in journals without IF, unless they are new journals.

b. Indicate acknowledgement to the Foundation or AIRC
   For each publication, please indicate whether it has an acknowledgement to AIRC or the Foundation (the box AIRC also comprises acknowledgements to the Foundation; the default is “NO”).

c. Certify accuracy of flags, and save records
   Once all selected publications have been flagged, scroll down to the bottom of the page and check the certification box (“I, the undersigned, certify that all publications have been carefully checked and correctly flagged for authorship. I am aware that any mistake or inaccuracy may impact the evaluation of my track record”). The system automatically recognizes the position of the applicant in the list of authors in each publication (if not, the box “not assignable” will be checked). It is possible to amend this information, if incorrect, by providing supporting documentation from the main page of the Publications (see below). Click on “Add selected publications” and then on “Close” to complete the process.

Add Web of Science® publications

From this section it is possible to enter articles that are included in Web of Science® but not in PubMed (most journals are present in both databases, but there are few exceptions; the drop-down menu does not list PubMed journals). For each record, please provide the title, list of authors, journal, year and month of publication, volume, pages. Select the journal from the drop-down menu, which provides all journals listed in Web of Science®. Mark each paper for authorship and acknowledgement to AIRC or to the Foundation. Please upload the page of the article where the role of the author in the published work is certified (not the entire manuscript). Finally, check the certification box and click on “Save” to complete the process.

Add papers in press

Use this section to submit articles already accepted for publication but not yet available online. For each record, please provide the title, list of authors, journal, year. Select the journal from the drop-down menu, which lists all Web of Science® indexed journals. Mark each paper for authorship and acknowledgement to AIRC or the Foundation. Please upload a PDF file with the letter of acceptance from the journal. Do not attach the entire manuscript. Finally, check the certification box and click on “Save” to complete the process. The IF of papers in press will not be included in the publications table.

Add from MyPub

This interface lists all publications previously entered into the system (either when submitting an application, or when submitting a grant renewal request, or directly into the MyPub section of the
Personal Area). By selecting some or all of these publications, they will be uploaded in the current application; please make sure the flags are correct.

All publications entered from any of the above sections will be listed in the “Publications” main page. From here, it is possible to edit the information relative to each paper by clicking on the title of the publication. Once in the “Edit publication flags” window, please check the appropriate authorship box and, if different from the default provided by the system, upload the page of the article where the role of the author in the published work is certified (e.g. for a second or third author who is in fact a co-first author, please upload the PDF file of the page where it is stated that the applicant “equally contributed to this work”). To complete the process, click on the certification box and click on “Save” to complete the process.

The system will automatically process all publication data to generate the complete list of publications in the PDF of the application, reporting the Impact Factor (IF) of the journals where each paper (with the exception of papers in press) was published.

The candidate is responsible for uploading the most accurate information regarding publications and authorship. The IF assigned to each article, regardless of the publication date, is the latest provided by Thomson Reuters. For this Call, the 2014 Thomson Reuters IF list will be used.

Candidates are required to check all the information and to contact the AIRC Peer Review Office before the deadline of the Call in order to correct any possible inaccuracy or mistake.

In case additional papers are accepted for publication after the submission deadline, the applicant may request permission from the Peer Review Office to add this supplementary information to his/her application. Please prepare a single PDF file containing a copy of the acceptance letter and a copy of the manuscript, and e-mail it to: airc.direzione-scientifica@airc.it.

All communications made in this regard by July 24th 2016 (5 PM Central European Time) will be forwarded to all reviewers evaluating the proposal. Any communication received after July 24th 2016 will not be taken into consideration.

**Project keywords**

Project keywords will be used by the Peer Review Office to assign each application to the most appropriate reviewers. Therefore, a good choice of keywords is extremely important to ensure that reviewers with the most adequate expertise will evaluate the application. Avoid keywords that are too generic or too similar with each other; pick a set of keywords that clearly define the key aspects of your research plan.

Keywords are listed at the end of this Call both in alphabetical order and by topic.

To enter the project keywords (at least one, maximum five) please click on the button “Enter/Edit Keywords”. In the “Manage Project Keywords” pop-up window, keywords are grouped by their first letter: for example, by clicking on the letter “C” in the menu it is possible to visualize all keywords beginning with the letter C, and to select one. Alternatively, type in a specific keyword in the “Search a specific keyword” box and click on “Search”. To select a keyword, click on it (the keyword box will turn from grey to blue) and then click on “Save”. Repeat this process for each keyword. To exit the window, click on “Close”.

**Research project**

The research project, agreed with the head of the hosting laboratory, must be divided into the following sections, all (with the exception of the Abstract) to be uploaded individually as PDF files:

a. Abstract (structured into: Background, Hypothesis, Aims, Experimental Design, Expected Results and Impact on Cancer. Either type in the text directly into each box, or use a Word processor and then cut and paste each section into the corresponding box; the system allows plain text only. The total number of words must not exceed 500)

b. Background (max 1 page, approx. 500 words)

c. Proposal main body (max 3 pages, approx. 1500 words)

d. Feasibility (max 1 page, approx. 500 words)
e. References (max 1 page, approx. 15 references).

Please make sure to propose a research plan that is consistent with the work of one person and with the projected duration of the fellowship. Proposals that look like a five-year grant requiring the work of several people will be judged not feasible and will be rated very low.

**Letter of acceptance of the Hosting Institution**

Please upload a letter, on letterhead paper, written and signed by the head of the hosting lab (max two pages in length, approx. 1000 words), addressed to the Peer Review Office. The letter MUST include the commitment that the following will be available:

- **necessary lab space and infrastructures**;
- **resources** (e.g. research grants held by the supervisor) to carry out the proposed research plan for the entire duration of the fellowship.
- **complementary skills training** (e.g. written skills for preparation of grants and papers, ethical issues and regulations in biotechnologies etc.) and **mentoring activities**. A specific training plan for the fellow (e.g. frequency of one-on-one meetings, lab meetings, participation to seminars and international congresses etc.) should be clearly described;
- **freedom to publish** the results of the research carried out during the fellowship appointment.

Please note that this document is particularly important as it represents the major source of information for reviewers on the mentoring and training opportunities that the fellow will receive. As such, it will impact the assessment of the “Quality of the Hosting Institution”, one of the major review criterion (see “The review process” above).

**Education and training of the head of the hosting lab**

Click on “Add new record” and list degrees and post-doctoral trainings of the head of the hosting lab (only the most relevant).

**Research and professional experience of the head of the hosting lab**

Click on “Add new record” and list the most relevant positions held by the head of the hosting lab.

**Publications of the head of the hosting lab**

A list of the most important publications of the head of the hosting lab, spanning 2011 to 2016, must be included. Click on “Add publications” and follow the prompt.

**Bio-Ethical Requirements**

Check boxes as applicable for human and animal experimentation.

**Research on humans**

Please note that the term “Research in humans” is not limited to clinical studies with healthy volunteers and/or patients. **It includes use of human biological samples** (commercially available human cell lines *e.g.* from ATCC are exempt), human genetic material and human data collection (*e.g.* genetic information, health, etc.).

If the research plan includes Research in humans, the approval of the local Ethics Committee or Institutional Review Board (IRB) is mandatory. **The authorization must be valid for the entire duration of the grant** and a copy of such authorization must be provided.

The approval document issued by the Ethics Committee MUST indicate:

- the date when the IRB meeting was held; **approvals obtained prior to 2013 are NOT accepted**, unless the study protocol is still active (supporting documentation might be requested to verify this is the case);
- the name of the applicant or of a unit of personnel or of a collaborator included in the application;
In case biospecimens have been obtained by external sources/collaborators, the clearance documents must be provided by the Ethics Committee of the collaborator’s research center.

If the IRB approval is available at the time of submission, check the box “I have obtained the clearance from the competent Ethics Committee/Institutional Review Board…” and upload it as PDF file by clicking on “Select” under the “Research on humans: clearance from Ethics Committee” header. Please indicate the date the approval was released and, if available, the date it expires; check the box “Valid for the duration of the project” if this is the case (supporting documentation might be requested to verify this condition is met).

If the approval from the Ethics Committee is not available by the submission deadline, the PI must obtain it by November 15th 2016, if possible, or in any case before the start of the fellowship. If the application is approved, the fellowship will start only after the provision of the approval to the funding bodies. Check the box “I have not obtained the clearance from the competent Ethics Committee/Institutional Review Board yet, but I will provide it…” and, when available, upload it as PDF file in the “Submissions” section of the AIRC account (click on “The following required actions are pending” and on the link “Upload required document”). Alternatively, please send it to the Peer Review Office by e-mail (airc.direzione-scientifica@airc.it).

**Research on animals**

Experimentation on animals (vertebrates, cephalopods and foetal forms of mammals) must conform to all regulations protecting animals used for research purposes. The animal protocol(s) must be evaluated and authorized by the competent authorities (i.e. the Italian Ministry of Health, if the animal experimentation will be carried out in the Hosting Institution or in the research lab of a collaborator based in Italy), and a copy of the authorization must be provided. More specifically:

- If the authorization was obtained before Italy incorporated the Directive 2010/63/EU into its national law with the D.Lgs. 26/2014 (March 29th, 2014), please provide a copy of the approval of the local Animal Ethics Committee or Institutional Animal Care and Use Committee, together with a certification that the proposal was sent to the Ministry of Health under the “Regime di comunicazione” protocol. In case a special authorization was required (“Decreto autorizzativo in regime di deroga”), please provide such authorization.
- If the authorization was obtained after Italy incorporated the Directive 2010/63/EU into its national law with the D.Lgs. 26/2014 (March 29th, 2014), please provide the authorization by the Ministry of Health.

In any case, the authorization to carry out in vivo studies must be valid for the entire duration of the fellowship appointment, or for at least the first year. If it expires during the course of the research project, a new approval must be provided to the funding bodies when submitting the request to renew the fellowship.

If the authorization is available at the time of the application submission, check the box “I have obtained the clearance from the Ministry of Health …” and upload it as PDF file by clicking on “Select” under the “Research on animals: Clearance from Ethics Committee” header. Please indicate the release and expiration date of the authorization in the appropriate boxes.

If the authorization is not available by the application submission deadline, the PI must obtain it before the start of the fellowship. Check the box “I have not obtained the clearance from the Ministry of Health yet, but I will provide it …” and, when available, upload it as PDF file in the “Submissions” section of the AIRC account: click on “The following required actions are pending” and on the link “Upload required document” and provide the requested documentation and information. Alternatively, please send it to the Peer Review Office by e-mail (airc.direzione-scientifica@airc.it).
Research that involves animal experimentation must comply with the principle of the Three Rs (3Rs) to Replace, Reduce and Refine the use of animals in research, as required by national and international rules. Please upload a document in the “Research on animals: Principles of the 3Rs” section, describing how the three Rs have been implemented in the research plan (e.g. explain why the anticipated results and benefits of the proposed research justify the use of animals, and why methods avoiding the use of living animals cannot be used; provide details and justification on the number of animals proposed for the research plan; describe all actions that will be taken to avoid or minimize pain and distress; etc.).

By signing the Bio-Ethical requirements page in the PDF file of the application, the applicant declares that the research studies are accurately described in the proposal and conform to all regulations protecting animals used for research purposes, including those of the D.Lgs. 26/2014, and that the experiments described in the proposal will be performed following the guidelines described in: Wolfensohn S, Lloyd M: "Handbook of Laboratory Animal Management and Welfare, 4th Edition" (Wiley-Blackwell, 2013).

Please note: Ethics Committee(s) approval(s) for human and/or animal research are not necessary for the assessment of the scientific merit of an application, during the review; however, if the application is approved, fellowships will be awarded only if the required Ethical Committee certifications have been sent to the funding bodies. AIRC and the Foundation are not responsible for any inaccuracy in the ethical documentation provided and does not accept any liability for harm to participants in funded trials.
Proposal PDF Draft
At any time during the application process a PDF draft file of the proposal can be generated and checked: go to “Check and Submit” (on the lower left of the main page), click on “Create draft” and then on “Open submission draft”. It is strongly suggested that after all forms have been correctly filled out, and prior to proceeding with the final submission, the PDF Draft and its content are carefully read, controlled and verified.

Final Full Proposal Submission
Online submission
To electronically submit the application, go to “Check and Submit” (on the lower left of the main page). All mandatory sections of the application form must be completed and must have a green flag before finalizing the submission. Only after having ascertained that all data are correctly reported in the PDF Draft of the proposal, please proceed to proposal submission by clicking on “Submit application”.

The application submitted will be available in PDF format in the “My submissions archive” section in of the Personal Area, and a copy should be saved for future reference.

Paper submission
For paper submission, please print only the following pages:
- Title page;
- Abstract;
- Bio-Ethical requirements page.

Sign and stamp in in the appropriate spaces or, in the case of the Abstract, please initial this page. The signatures of the candidate and of the Legal representative are both required in the Title page. By signing the Title page, the candidate and the Legal representative acknowledge and agree to all terms and conditions of this Call.
In addition, the Legal representative declares that should the application be funded, the fellow will be affiliated with the Hosting Institution for the entire duration of the fellowship and will be allowed to carry out the research project in the Hosting Institution. Paper documentation marked with “draft” is not valid. Please print the requested pages only after completion of the submission online.

Send these pages to:

Fondazione Italiana per la Ricerca sul Cancro - AIRC
Peer Review Office
via San Vito 7
20123 Milano

If these documents are not sent by the indicated deadline, or if the Foundation does not receive them, applications will not be sent out for review.
Template - Convenzione per l’erogazione di borse di studio finanziate dalla Fondazione Italiana per la Ricerca sul Cancro - AIRC

TRA

La Fondazione Italiana per la Ricerca sul Cancro – AIRC (nel seguito: la Fondazione), con sede in, codice fiscale qui rappresentata dal Legale Rappresentante, nato a, il, domiciliato per la carica presso la sede

e

(Istituzione), in qualità di Istituzione ospitante titolari di borse di studio istituite dalla Fondazione (nel seguito: Istituzione), avente sede in (indirizzo completo: città/provincia), C.F./PARTITA IVA, rappresentato da (nome del rappresentante legale), (funzione),

Nel seguito: Parti

PREMESSO CHE

1. La Fondazione è un ente morale senza finalità di lucro, con lo scopo esclusivo di promuovere la ricerca scientifica nel campo della cura e dello studio dei tumori, accogliendo lasciti testamentari e donazioni.

2. L’Istituzione è un Organismo di Ricerca che svolge attività di ricerca biomedica, non economica, oncologica o di interesse oncologico e soddisfa i requisiti previsti per la “Hosting Institution” indicati nel bando. Per Organismo di Ricerca si intende un’entità (ad esempio, università, ospedale o istituto di ricerca), indipendentemente dal suo status giuridico (costituito secondo il diritto privato o pubblico), la cui finalità principale consiste nello svolgere in maniera indipendente attività di ricerca non economica. Gli eventuali utili derivanti dall’attività di ricerca non economica devono essere reinvestiti in attività di ricerca non economica. Qualora tale entità svolga anche attività economiche, il finanziamento, i costi e i ricavi di tali attività economiche devono formare oggetto di contabilità separata. Le imprese in grado di esercitare un’influenza determinante su tale entità, ad esempio in qualità di azionisti o di soci, non possono godere di alcun accesso preferenziale ai risultati generati.

3. La Fondazione pubblica ogni anno bandi per l’assegnazione di borse di studio, che invitano i ricercatori a presentare le proprie candidature.

4. I ricercatori assegnatari di borsa di studio sono selezionati ad esclusiva cura della Fondazione, attraverso un severo processo di valutazione, basato su criteri esclusivamente meritocratici. Le candidature presentate alla Fondazione sono valutate tramite il metodo internazionale del peer review (o valutazione da parte di pari); ogni candidatura è sottoposta al giudizio di almeno tre esperti indipendenti che non hanno conflitto di interesse con il richiedente. Tali revisori sono parte di un gruppo di quasi 600 esperti internazionali e/o sono membri del Comitato Tecnico Scientifico, scelti per la loro expertise in campo oncologico.

5. L’attività di ricerca proposta dai titolari della borsa di studio deve essere svolta presso enti senza scopo di lucro che abbiano tra le proprie finalità statutarie la conduzione di attività di ricerca scientifica e che operino in campo oncologico, e che abbiano manifestato la propria disponibilità a consentire lo svolgimento del progetto proposto dal ricercatore in risposta al Bando pubblicato dalla Fondazione, con propria organizzazione di beni e servizi.

6. La Fondazione intende mettere a disposizione dell’Istituzione ospitante l’importo lordo di ciascuna borsa di studio assegnata.
Alla luce di tutto quanto precede, al fine di disciplinare le modalità di erogazione del contributo finanziario e gli impegni di ciascuna parte a seguito dell’attribuzione del contributo,

le parti

CONVENGONO

le condizioni specificate nella seguente convenzione (nel seguito: “convenzione”).

**Articolo 1 - Modalità di comunicazione degli assegnatari**
La Fondazione invierà all’Istituzione ospitante entro la fine di ogni anno l’elenco dei borsisti assegnatari di borsa di studio per l’anno successivo.

**Articolo 2 - Modalità di erogazione del contributo**
L’erogazione del contributo finanziario annuale da parte della Fondazione avverrà con trasferimenti trimestrali anticipati (31.12 - 31.03 - 30.06 - 30.09) delle somme necessarie al pagamento delle borse di studio da erogare nel trimestre successivo.
L’Istituzione chiede che i trasferimenti trimestrali anticipati effettuati a mezzo bonifico bancario avvengano sul seguente conto:

**BANCA:**
**INTESTATARIO CONTO CORRENTE:**
**IBAN:**
L’Istituzione si impegna a comunicare tempestivamente le eventuali variazioni delle proprie coordinate bancarie a mezzo posta raccomandata.

**Articolo 3 - Modalità di erogazione della borsa di studio al ricercatore**
L’Istituzione si impegna ad erogare, con cadenza mensile, l’importo assegnato ai ricercatori selezionati dalla Fondazione, al netto delle eventuali trattenute fiscali e contributive a carico del titolare della borsa di studio, provvedendo alla relativa certificazione dei compensi, in qualità di sostituto d’imposta.
In funzione dell’importo messo a disposizione dalla Fondazione, l’Istituzione concorderà con ciascun assegnatario della borsa di studio la modalità di erogazione ed il trattamento fiscale più vantaggioso per quest’ultimo tra le opzioni consentite dalla legge vigente, scegliendo se attivare borse di ricerca, assegni di ricerca o altre forme contrattuali compatibili con l’importo assegnato. Gli ulteriori oneri fiscali, contributivi ed assicurativi restano a carico dell’Istituzione, la quale si impegna a non trattenere ai borsisti alcun onere di carattere amministrativo.
L’Istituzione ha facoltà di integrare l’importo lordo della borsa con fondi propri, a condizione che tali fondi non siano riconducibili ad altre erogazioni da parte di AIRC.

**Articolo 4 – Responsabilità dell’Istituzione**
Ogni responsabilità ed onere legato allo svolgimento del progetto da parte del borsista è a carico dell’Istituzione.
Nello svolgimento delle attività di ricerca e per l’effettuazione delle relative spese, l’istituzione opererà in piena autonomia, secondo le norme di legge e regolamenti vigenti, assumendone la completa responsabilità; pertanto la Fondazione resterà estranea ad ogni rapporto comunque nascente con terzi (personale dipendente, creditori, collaboratori interni o esterni, fornitori, ecc…) in relazione allo svolgimento del programma della borsa di studio e sarà totalmente estranea a responsabilità per eventuali danni riconducibili ad attività direttamente o indirettamente connesse alla borsa di studio.
L’erogazione della borsa di studio deve avvenire in ottemperanza alla normativa vigente.
L’Istituzione si impegna ad applicare ai titolari della borsa di studio, le tutele previste dal d.lgs. 81/2008 in materia di prevenzione e sicurezza degli ambienti di lavoro. L’Istituzione si impegna a dare idonea copertura assicurativa contro eventuali infortuni ai borsisti ospitati e per l’attività da loro svolta.
L’Istituzione si impegna inoltre a garantire ai borsisti ospitati la disponibilità di spazi e mezzi necessari allo svolgimento dell’attività di ricerca per cui è stata assegnata loro la borsa di studio e un’adeguata formazione sotto la supervisione del responsabile scientifico indicato nella candidatura/nell’applicazione.

Articolo 5 – Responsabilità della Fondazione
L’erogazione del contributo finanziario avverrà nei limiti dell’importo assegnato annualmente per le borse di studio elencate nella comunicazione di cui all’articolo 1. Eventuali maggiori oneri, connessi allo svolgimento dell’attività del borsista, resteranno a carico dell’Istituzione.

Articolo 6 – Gestione delle variazioni delle condizioni di svolgimento della borsa di studio
Eventuali modifiche delle condizioni di svolgimento della borsa di studio dovranno essere preventivamente autorizzate dalla Direzione Scientifica, a cui dovrà essere inviata, per tempo, formale richiesta a mezzo e-mail, scrivendo all’indirizzo: airc.direzione-scientifica@pec.it.

Qualora abbia luogo una interruzione dell’attività di progetto per un periodo superiore a 40 giorni consecutivi (ad esempio per documentata maternità o malattia), la borsa sarà sospesa con facoltà di recupero.
L’istituzione dovrà informare tempestivamente la Fondazione, comunicando il periodo di astensione dall’attività di ricerca e l’eventuale recupero concordato con il borsista. Durante il periodo di sospensione la Fondazione sospenderà l’erogazione del contributo, che sarà posticipata al periodo di recupero.

L’eventuale rinuncia alla borsa di studio da parte di un borsista dovrà essere comunicata dall’Istituzione ospitante alla Fondazione via e-mail all’indirizzo indicato sopra ed a mezzo raccomandata A.R. alla Direzione Scientifica in via San Vito 7, Milano, non appena ne venga a conoscenza. A seguito di tale comunicazione la Fondazione sospenderà l’erogazione dei relativi fondi.
A seguito della rinuncia alla borsa di studio da parte del titolare, il relativo progetto terminerà. L’istituto si impegna a restituire alla Fondazione entro i due mesi successivi alla comunicazione di rinuncia da parte del borsista, l’eventuale residuo non corrisposto a mezzo bonifico bancario sul seguente conto corrente:

BANCA:
INTESTATARIO CONTO CORRENTE:
IBAN:

Articolo 7 – Acknowledgements
Le pubblicazioni scientifiche contenenti i risultati della ricerca svolta dal borsista dovranno recare il riconoscimento alla Fondazione tra gli “acknowledgements” o il “funding”; analogamente eventuali interviste o articoli rilasciati sulla ricerca svolta dal borsista a media generalisti (televisioni, radio, giornali, siti Internet) dovranno recare la citazione del sostegno da parte della Fondazione.

Articolo 8 – Durata
La presente convenzione ha la durata di anni cinque, a decorrere dalla data dell’ultima sottoscrizione delle Parti, e si intenderà tacitamente rinnovata per un periodo di cinque anni; le parti si riservano in ogni momento la facoltà di recesso da comunicarsi mediante lettera raccomandata con un preavviso di sei mesi.

Articolo 9 – Tutela della Privacy
Le Parti dichiarano reciprocamente di essere informate e, per quanto di ragione, espressamente acconsentire, che i “dati personali” forniti, anche verbalmente per l’attività preconvenzionale o, comunque, raccolti in conseguenza e nel corso dell’esecuzione della presente Convenzione, vengano trattati esclusivamente per le finalità della Convenzione, mediante consultazione,
elaborazione, interconnessione, raffronto con altri dati e/o ogni ulteriore elaborazione manuale e/o
automatizzata e, inoltre, per fini statistici, con esclusivo trattamento dei dati in forma anonima,
mediante comunicazione a soggetti pubblici, quando ne facciano richiesta per il perseguimento dei
propri fini istituzionali, nonché a soggetti privati, quando lo scopo della richiesta sia compatibile
con i fini istituzionali delle Parti.
Titolari, per quanto concerne il presente articolo, sono le Parti come sopra individuate, denominate
e domiciliate.
Le Parti dichiarano, infine, di essere informate sui diritti sanciti dall’art. 7, del d.lgs. 30.06.2003, n. 196.

Articolo 10 – Comunicazioni
Ogni comunicazione inerente l’oggetto della convenzione o la richiesta di modifica delle condizioni
della stessa, dovrà essere tempestivamente inviata a mezzo raccomandata A.R. indirizzata alla
Fondazione.
L’Istituzione si impegna a comunicare tempestivamente alla Fondazione ogni variazione dello stato
giuridico dell’Ente stesso e del rapporto tra l’Ente e il borsista. L’Istituzione ha l’obbligo di
informare tempestivamente alla Fondazione di qualsiasi modifica intervenuta nello svolgimento del
progetto, in particolare di qualunque variazione del ruolo del borsista nell’Istituzione o suo
trasferimento. Dovranno inoltre essere trasmesse tempestivamente alla Fondazione le eventuali
modifiche incorse nell’assetto giuridico (quali, a titolo esemplificativo, ma non esaustivo,
variazioni nella personalità giuridica, fusioni, incorporazioni, liquidazioni volontarie, ecc…) o
qualunque rilevante variazione a carico degli organi amministrativi; analogamente dovrà essere
comunicata tempestivamente l’eventuale cessazione dell’attività, l’insorgenza di procedure
concorsuali, o qualunque altro evento che possa pregiudicare l’affidabilità economico finanziaria
dell’Istituzione.

Articolo 11 - Risoluzione delle controversie
Le Parti concordano di definire amichevolmente qualsiasi vertenza che possa nascere
dall’interpretazione della presente Convenzione che è retta e disciplinata unicamente dalla Legge
italiana.
Se quanto stabilito al comma precedente non risultasse sufficiente a risolvere la vertenza, le Parti
sottoporranno al tentativo di conciliazione previsto dal Servizio di Conciliazione della Camera
Arbitrale di Milano qualsiasi controversia irrisolta derivante dalla presente Convenzione o in
relazione alla stessa.
In caso di mancato raggiungimento di un accordo dopo il ricorso alla procedura di conciliazione
sopra indicata, le Parti saranno libere di adire l’Autorità Giudiziaria Ordinaria. Foro competente in
tal caso sarà unicamente quello di Milano.

Articolo 12 - Documenti che integrano la presente convenzione
La documentazione che disciplina i rapporti tra la Fondazione e l’Istituzione in relazione ai progetti
elencati nella lettera citata all’art. 1 (Bando, Applications, Lettere di Assegnazione, ecc.) ha validità
ai fini della determinazione dei termini dell’accordo tra le parti.
KEYWORDS IN ALPHABETICAL ORDER

Acute Lymphoblastic Leukemia (ALL)  CD133/Stem cell markers
Acute Myeloid Leukemia (AML)  Cell adhesion and/or cell adhesion molecules
Adenovirus  Cell cycle
Adjuvant therapy  Cell cycle checkpoint G1/S
Aging and cancer  Cell cycle checkpoint G2/M
AIDS/HIV/Kaposi  Cell differentiation and/or differentiation therapy
Androgen and/or receptors  Cell migration, motility and/or invasion
Aneuploidy  Cell polarity
Angiogenesis and/or vasculogenesis  Cell signaling
Animal models  Centrosome
Anti-angiogenic therapy  Cervix or endometrial ca.
Antibody/mAb therapy  Chemistry
Apoptosis  Chemoimmunotherapy
Aromatase and/or inhibitors  Chemokines
ATM pathway  Chemotherapy and/or chemotherapic drugs
ATR pathway  Chromatin remodeling
Autoimmunity/Autoantibodies  Chronic Lymphocytic Leukemia (CLL)
Autophagy  Chronic Myeloid Leukemia (CML)
B cells  Circulating tumor cells
bcl2 family  Clinical practice guidelines
BCR-Abl/Abl  Clinical trials
Biochemistry  Colorectal and/or Intestinal ca.
Bioinformatics  Combination therapy
Biomarkers  Comparative genomics hybridization (CGH)
Biomolecular modelling  Computational biology
Biophysics  Computer Tomography (CT Scan)
Bladder tumor  Costimulatory molecules
Body mass index (BMI) and/or obesity  COX2
Bone disease  Crosstalk
Bone morphogenetic protein (BMP)  Crystallography
BRAF/RAF kinases  Cyclic AMP
Brain and/or nervous system tumors  Cyclins and/or inhibitors
BRCA  Cytogenetics and/or chromosome alterations
Breast ca.  Cytokines/Interleukins
Burkitt lymphoma  Cytokinesis
C.elegans  Cytoskeleton
Cachexia  Cytotoxic T Lymphocytes (CTL)
Caderhins  Dendritic cells
Cancer evolution  Diagnosis
Cancer stem cells  Diet
Carcinogenesis  DNA damage
Caspases  DNA double strand break repair (DSBR)
Caveolin  DNA methylation
KEYWORDS IN ALPHABETICAL ORDER

DNA recombination
DNA repair
DNA replication
DNA single strand break repair (SSBR)
Docking
Drosophila
Drug delivery
Drug discovery and/or development
Drug response and/or resistance
Drug screening
Drug toxicity
EGF and/or receptors
Embryonic development
Endocrinology
Endocytosis
Endoplasmic reticulum (ER)
Endothelial cells
Epidemiology
Epigenetics
Epithelial mesenchyme transition (EMT)
Epstein-Barr Virus (EBV)
Estrogens and/or receptors
Exosomes and/or endogenous microvesicles
Extracellular Matrix (ECM)/Stroma
Fas and/or FasL
Fatty acids
FGF and/or receptor
Flow cytometry
Fluence imaging system
Fluorescence in situ hybridization (FISH)
Fluorescence resonance energy transfer (FRET)
Focal Adhesion/FAK
Folate and/or receptor
Functional genomics
Functional validation of target genes
Fusion genes
Gastric ca.
Gene alteration/gain or loss
Gene expression and/or profile
Gene regulation
Gene therapy
Genetics
Genome wide screening/GWAS
Genomic imprinting
Genomic/Genetic instability
Genomics
Genotoxicity
Glioma and/or glioblastoma
Glucocorticoids and/or receptors
Glucose metabolism and/or Warburg effect
Glycoproteins and/or glycosylation
Golgi
G-proteins and/or GPCR
Granulocytes
Growth factors and/or receptors
Growth induction and/or growth arrest
GVDH and/or Graft versus Tumor
Gynecological tumors
Head and neck ca.
Heat shock proteins (HSP)
Hedgehog pathway
Hematologic malignancies
Hematopoiesis
Hematopoietic stem cells
Hemostasis and thrombosis
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Hepatocellular carcinoma (HCC)
HER1-2-3-4
Hereditary DNA repair disorders
Hereditary tumors
Herpes virus
High Mobility Group Proteins (HMG)
Hippo pathway
Histone modifications
HLA/Major Histocompatibility Complex (MHC)
Hodgkin's lymphoma
Homologous recombination
Hormones
Human Papilloma Virus (HPV)
Hypoxia/Hypoxia-inducible Factors (HIF-1)
Immune escape
Immunization
Immuono-editing
Immunohistochemistry
Immunosuppression and/or suppressor cells
KEYWORDS IN ALPHABETICAL ORDER

Immunotherapy
In vitro imaging and/or live cell imaging
In vivo imaging
Infection
Inflammation and/or inflammatory cytokines
Inhibitor of apoptosis proteins (IAPs)
Innate immunity
Insulin
Insulin-like growth factor (IGF) and/or receptors
Integrins and/or Integrin-linked kinase (ILK)
Interferons
Ion channels
Jak/Stat pathway
Kidney ca.
Kinase/Kinome
Lentivirus
Leukaemia
Lipid metabolism
Lipidic mediators
Lipoxygenases
Liver development and/or regeneration
Loss of heterozygosity (LOH)
Lung ca.
Lymphatics and/or lymphangiogenesis
Lymphocyte differentiation
Lymphomas
Macrophages and/or monocytes
Magnetic resonance imaging (MRI)
MAP Kinases
Mass spectrometry
Mathematical modeling
Mathematical oncology
Matrix metalloproteases (MMP) and/or inhibitors
MDM2
Medulloblastoma
Melanoma
Membrane biology
Mesothelioma
MET/HGF
Metabolism/Metabolomics
Metallo-drugs
Metastasis
Microarrays

Microbiome
Microenvironment
microRNA
Microscopy
Minimal Residual Disease (MRD)
Mitochondria
Mitosis
Monoclonal antibodies (mAbs) and/or immunoconjugates
Mouse models
mRNA processing
mRNA translation
Multidrug resistance (MDR)
Mutation (somatic and/or germline)
Myc
Myeloma
Nanotechnology/Nanoparticles
Netrin receptors
Neuroblastoma
Neuroendocrine tumors
Next generation sequencing
NF-kB family
Nitric oxide
NK and/or NKT cells
NMR spectroscopy
Non apoptotic cell death
Non melanoma skin tumors
Normal stem cells
Notch pathway
Nuclear medicine
Nuclear receptor
Nuclear structures
Oncogenes
Oncogenic virus/Viral oncology
Organic compounds
Osteopontin
Osteosarcoma
Ovarian ca.
Oxidative stress and/or Reactive Oxygen Species (ROS)
p21 - activated kinases (PAK)
p53, p63, p73
Palliative care
Pancreas ca.
Pathology
KEYWORDS IN ALPHABETICAL ORDER

Patient risk stratification, RNA splicing
PDGF and/or receptors, Sarcoma
Pediatric tumors, Screening
Peptides as drugs, Senescence
Peroxisome proliferator-activated receptor (PPAR), Side effects
PET and/or PET-CT, Signal transduction inhibitors
Phage display, siRNA and/or non coding RNA
Phagocytes and/or phagocytosis, Small molecule inhibitors
Pharmacogenetics/Pharmacogenomics, Smoking
Pharmacokinetics, Soft tissue tumors
Pharmacology, Solid tumors
Phosphatases, SPECT
Phospholipids, Spheroids/3D cultures
Phosphorylation, Src family
Photodynamic therapy and photodetection, Staging
Photonics, Statistics
PI3K/Akt/PTEN/mTOR pathway, Stress response
Poly-ADP-ribose polymerase (PARP), SUMO and/or sumoylation
Polymorphisms/SNPs, Surgery
Post-translational modification, Survival analysis
Precancerous lesions, Synthetic lethality
Preclinical studies, Systems biology
Prevention and/or chemoprevention, T cells/TCR
Prognosis, T helpers
Prostaglandins, Target therapy
Prostate ca., Telomere and/or telomerase
Proteasome, Testis ca.
Protein microarrays, TGF and/or receptors
Proteomics, Thymoma
Proteomics, Thyroid ca.
Radiosensitivity and/or resistance, Thyroid hormone
Radiotherapy, Tissue microarrays (TMA)
Radiotoxicity, TNF and/or receptors
RAS/RAS inhibitors, Tolerance
Rb/Rb family, Toll-like receptors (TLR)
Response and/or resistance to therapy, Topoisomerase
RET, TRAIL
Retinoblastoma, Transcription
Retinoic acid and/or receptors, Transcription factors
Retrospective studies, Transformation assays
Rho GTPases family, Transgenic mice
Risk factors, Translesion synthesis
RNA binding proteins, Translocation
KEYWORDS IN ALPHABETICAL ORDER

Transplantation
Treg cells
Triple negative breast ca.
Tumor antigen
Tumor dormancy
Tumor-infiltrating Lymphocytes (TIL)
Tumor suppressor genes
Tumor-stroma interaction
Tyrosine kinase receptors (TKR) and/or inhibitors
Ubiquitin and/or ubiquitination
Ultrasound
Urokinase-Plasminogen System (uPA, uPAR, PAI)
Vaccine
VEGF and/or receptor
Virology
Von Hippel-Lindau (VHL)
Wilms' Tumor Gene (WT1)
Wnt/beta-catenin pathway
Xenopus
Yeast
Zebrasfish
### KEYWORDS BY TOPIC

<table>
<thead>
<tr>
<th><strong>Adhesion and stroma</strong></th>
<th><strong>Angiogenesis</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cadherins</td>
<td>Angiogenesis and/or vasculogenesis</td>
</tr>
<tr>
<td>Caveolin</td>
<td>Endothelial cells</td>
</tr>
<tr>
<td>Cell adhesion and/or cell adhesion molecules</td>
<td>Hypoxia/Hypoxia-inducible Factors (HIF-1)</td>
</tr>
<tr>
<td>Cell migration, motility and/or invasion</td>
<td>Lymphatics and/or lymphangiogenesis</td>
</tr>
<tr>
<td>Cell polarity</td>
<td>VEGF and/or receptor</td>
</tr>
<tr>
<td>Cytoskeleton</td>
<td>Von Hippel-Lindau (VHL)</td>
</tr>
<tr>
<td>Extracellular Matrix (ECM)/Stroma</td>
<td></td>
</tr>
<tr>
<td>Focal Adhesion/FAK</td>
<td></td>
</tr>
<tr>
<td>Integrins and/or Integrin-linked kinase (ILK)</td>
<td></td>
</tr>
<tr>
<td>Matrix metalloproteases (MMP) and/or inhibitors</td>
<td></td>
</tr>
<tr>
<td>Microenvironment</td>
<td></td>
</tr>
<tr>
<td>Osteopontin</td>
<td></td>
</tr>
<tr>
<td>Tumor-stroma interaction</td>
<td></td>
</tr>
<tr>
<td>Urokinase-Plasminogen System (uPA, uPAR, PAI)</td>
<td></td>
</tr>
<tr>
<td>Cell death and apoptosis</td>
<td>Clinical topics</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>Apoptosis</td>
<td>Cachexia</td>
</tr>
<tr>
<td>Autophagy</td>
<td>Computer Tomography (CT Scan)</td>
</tr>
<tr>
<td>bcl2 family</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>Caspases</td>
<td>Drug toxicity</td>
</tr>
<tr>
<td>Fas and/or FasL</td>
<td>Endocrinology</td>
</tr>
<tr>
<td>Inhibitor of apoptosis proteins (IAPs)</td>
<td>GVHD and/or Graft versus Tumor</td>
</tr>
<tr>
<td>Mitochondria</td>
<td>Hemostasis and thrombosis</td>
</tr>
<tr>
<td>Non apoptotic cell death</td>
<td>Magnetic resonance imaging (MRI)</td>
</tr>
<tr>
<td>p53, p63, p73</td>
<td>Metastasis</td>
</tr>
<tr>
<td>Senescence</td>
<td>Minimal Residual Disease (MRD)</td>
</tr>
<tr>
<td>TRAIL</td>
<td>Nuclear medicine</td>
</tr>
<tr>
<td></td>
<td>Palliative care</td>
</tr>
<tr>
<td></td>
<td>Patient risk stratification</td>
</tr>
<tr>
<td></td>
<td>Pathology</td>
</tr>
<tr>
<td></td>
<td>PET and/or PET-CT</td>
</tr>
<tr>
<td></td>
<td>Prognosis</td>
</tr>
<tr>
<td></td>
<td>Retrospective studies</td>
</tr>
<tr>
<td></td>
<td>Side effects</td>
</tr>
<tr>
<td></td>
<td>SPECT</td>
</tr>
<tr>
<td></td>
<td>Staging</td>
</tr>
<tr>
<td></td>
<td>Survival analysis</td>
</tr>
<tr>
<td></td>
<td>Ultrasound</td>
</tr>
<tr>
<td></td>
<td>Transplantation</td>
</tr>
</tbody>
</table>
**KEYWORDS BY TOPIC**

<table>
<thead>
<tr>
<th>Genes, proteins and miscellanea</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATM pathway</td>
</tr>
<tr>
<td>ATR pathway</td>
</tr>
<tr>
<td>BCR-Abl/Abl</td>
</tr>
<tr>
<td>Bone morphogenetic protein (BMP)</td>
</tr>
<tr>
<td>BRAF/RAF kinases</td>
</tr>
<tr>
<td>BRCA</td>
</tr>
<tr>
<td>Embryonic development</td>
</tr>
<tr>
<td>Endocytosis</td>
</tr>
<tr>
<td>Endoplasmic reticulum (ER)</td>
</tr>
<tr>
<td>Epigenetics</td>
</tr>
<tr>
<td>Epithelial mesenchyme transition (EMT)</td>
</tr>
<tr>
<td>Exosomes and/or endogenous microvesicles</td>
</tr>
<tr>
<td>Fatty acids</td>
</tr>
<tr>
<td>FGF and/or receptor</td>
</tr>
<tr>
<td>Glucocorticoids and/or receptors</td>
</tr>
<tr>
<td>Glucose metabolism and/or Warburg effect</td>
</tr>
<tr>
<td>Glycoproteins and/or glycosylation</td>
</tr>
<tr>
<td>Golgi</td>
</tr>
<tr>
<td>Heat shock proteins (HSP)</td>
</tr>
<tr>
<td>High Mobility Group Proteins (HMG)</td>
</tr>
<tr>
<td>Ion channels</td>
</tr>
<tr>
<td>Lipidic mediators</td>
</tr>
<tr>
<td>Lipid metabolism</td>
</tr>
<tr>
<td>Lipoxygenases</td>
</tr>
<tr>
<td>Liver development and/or regeneration</td>
</tr>
<tr>
<td>MDM2</td>
</tr>
<tr>
<td>Membrane biology</td>
</tr>
<tr>
<td>Microbiome</td>
</tr>
<tr>
<td>Myc</td>
</tr>
<tr>
<td>Netrin receptors</td>
</tr>
</tbody>
</table>
KEYWORDS BY TOPIC

Genetics
Aneuploidy
Cancer evolution
Centromosome
Chromatin remodeling
Cytogenetics and/or chromosome alterations
DNA damage
DNA double strand break repair (DSBR)
DNA methylation
DNA recombination
DNA repair
DNA replication
DNA single strand break repair (SSBR)
Functional genomics
Fusion genes
Gene alteration/gain or loss
Gene expression and/or profile
Gene regulation
Genetics
Genome wide screening/GWAS
Genomic imprinting
Genomic/Genetic instability
Genomics
Hereditary DNA repair disorders
Histone modifications
Homologous recombination
Loss of heterozygosity (LOH)
microRNA
Mitosis
mRNA processing
mRNA translation
Mutation (somatic and/or germline)

Nuclear structures
Pharmacogenetics/Pharmacogenomics
Polymorphisms/SNPs
Post-translational modification
RNA splicing
siRNA and/or non coding RNA
Synthetic lethality
Transcription
Transcription factors
Transformation assays
Translesion synthesis
Translocation
Tumor suppressor genes
### Immunochemistry

<table>
<thead>
<tr>
<th>Immunology</th>
<th>Autoimmunity/Autoantibodies</th>
<th>Toll-like receptors (TLR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B cells</td>
<td>Treg cells</td>
<td></td>
</tr>
<tr>
<td>Chemokines</td>
<td>Tumor antigen</td>
<td></td>
</tr>
<tr>
<td>Costimulatory molecules</td>
<td>Tumor dormancy</td>
<td></td>
</tr>
<tr>
<td>COX2</td>
<td>Tumor-Infiltrating Lymphocytes (TIL)</td>
<td></td>
</tr>
<tr>
<td>Cytokines/Interleukins</td>
<td>Vaccine</td>
<td></td>
</tr>
<tr>
<td>Cytotoxic T Lymphocytes (CTL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dendritic cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granulocytes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematopoiesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA/Major Histocompatibility Complex (MHC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune escape</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immuno-editing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunosuppression and/or suppressor cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation and/or inflammatory cytokines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Innate immunity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interferons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophages and/or monocytes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monoclonal antibodies (mAbs) and/or immunoconjugates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NF-kB family</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NK and/or NKT cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phagocytes and/or phagocytosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostaglandins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T cells/TCR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T helpers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF and/or receptors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tolerance</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Methods

<table>
<thead>
<tr>
<th>Animal models</th>
<th>Phage display</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biochemistry</td>
<td>Photodynamic therapy and photodetection</td>
</tr>
<tr>
<td>Bioinformatics</td>
<td>Photonics</td>
</tr>
<tr>
<td>Biomolecular modelling</td>
<td>Protein microarrays</td>
</tr>
<tr>
<td>Biophysics</td>
<td>Proteomics</td>
</tr>
<tr>
<td>C.elegans</td>
<td>Spheroids/3D cultures</td>
</tr>
<tr>
<td>Chemistry</td>
<td>Statistics</td>
</tr>
<tr>
<td>Comparative genomics hybridization (CGH)</td>
<td>Systems biology</td>
</tr>
<tr>
<td>Computational biology</td>
<td>Tissue microarrays (TMA)</td>
</tr>
<tr>
<td>Crystallography</td>
<td>Transgenic mice</td>
</tr>
<tr>
<td>Docking</td>
<td>Xenopus</td>
</tr>
<tr>
<td>Drosophila</td>
<td>Yeast</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>Zebrfish</td>
</tr>
<tr>
<td>Flow cytometry</td>
<td></td>
</tr>
<tr>
<td>Fluorescence imaging system</td>
<td></td>
</tr>
<tr>
<td>Fluorescence in situ hybridization (FISH)</td>
<td></td>
</tr>
<tr>
<td>Fluorescence resonance energy transfer (FRET)</td>
<td></td>
</tr>
<tr>
<td>Functional validation of target genes</td>
<td></td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td></td>
</tr>
<tr>
<td>In vitro imaging and/or live cell imaging</td>
<td></td>
</tr>
<tr>
<td>In vivo imaging</td>
<td></td>
</tr>
<tr>
<td>Mass spectrometry</td>
<td></td>
</tr>
<tr>
<td>Mathematical modeling</td>
<td></td>
</tr>
<tr>
<td>Mathematical oncology</td>
<td></td>
</tr>
<tr>
<td>Microarrays</td>
<td></td>
</tr>
<tr>
<td>Microscopy</td>
<td></td>
</tr>
<tr>
<td>Mouse models</td>
<td></td>
</tr>
<tr>
<td>Nanotechnology/Nanoparticles</td>
<td></td>
</tr>
<tr>
<td>Next generation sequencing</td>
<td></td>
</tr>
<tr>
<td>NMR spectroscopy</td>
<td></td>
</tr>
</tbody>
</table>

## Risk factors

| Aging and cancer | |
| Biomarkers | |
| Body mass index (BMI) and/or obesity | |
| Carcinogenesis | |
| Diet | |
| Genotoxicity | |
| Metabolism/Metabolomics | |
| Organic compounds | |
| Oxidative stress and/or Reactive Oxygen Species (ROS) | |
| Precancerous lesions | |
| Prevention and/or chemoprevention | |
| Risk factors | |
| Screening | |
| Smoking | |
KEYWORDS BY TOPIC

Signaling and cell cycle
- Androgen and/or receptors
- Cell cycle
- Cell cycle checkpoint G1/S
- Cell cycle checkpoint G2/M
- Cell differentiation and/or differentiation therapy
- Cell signaling
- Crosstalk
- Cyclic AMP
- Cyclins and/or inhibitors
- Cytokinesis
- EGF and/or receptors
- Estrogens and/or receptors
- Folate and/or receptor
- G-proteins and/or GPCR
- Growth factors and/or receptors
- Growth induction and/or growth arrest
- Hedgehog pathway
- HER1-2-3-4
- Hippo pathway
- Hormones
- Insulin
- Insulin-like growth factor (IGF) and/or receptors
- Jak/Stat pathway
- Kinase/Kinome
- MAP Kinases
- MET/HGF
- Notch pathway
- Nuclear receptor
- PDGF and/or receptors
- Peroxisome proliferator-activated receptor (PPAR)
- Phosphorylation
- PI3K/Akt/PTEN/mTOR pathway

RAS/RAS inhibitors
- Rb/Rb family
- RET
- Retinoic acid and/or receptors
- Rho GTPases family
- Src family
- TGF and/or receptors
- Thyroid hormone
- Tyrosine kinase receptors (TKR) and/or inhibitors
- Wnt/Beta-catenin pathway

Stem cells
- Cancer stem cells
- CD133/Stem cell markers
- Circulating tumor cells
- Hematopoietic stem cells
- Normal stem cells
Types of tumors
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Bladder tumor
Bone disease
Brain and/or nervous system tumors
Breast ca.
Burkitt lymphoma
Cervix or endometrial ca.
Chronic Lymphocytic Leukemia (CLL)
Chronic Myeloid Leukemia (CML)
Colorectal and/or Intestinal ca.
Gastric ca.
Glioma and/or glioblastoma
Gynecological tumors
Head and neck ca.
Hematologic malignancies
Hepatocellular carcinoma (HCC)
Hereditary tumors
Hodgkin's lymphoma
Kidney ca.
Leukaemia
Lung ca.
Lymphomas
Medulloblastoma
Melanoma
Mesothelioma
Myeloma
Neuroblastoma
Neuroendocrine tumors
Non melanoma skin tumors
Osteosarcoma
Ovarian ca.
Pancreas ca.
Pediatric tumors
Prostate ca.
Retinoblastoma
Sarcoma

Therapies
Adjuvant therapy
Anti-angiogenic therapy
Antibody/mAb therapy
Aromatase and/or inhibitors
Chemoimmunotherapy
Chemotherapy and/or chemotherapeutic drugs
Clinical practice guidelines
Clinical trials
Combination therapy
Drug delivery
Drug discovery and/or development
Drug response and/or resistance
Drug screening
Gene therapy
Immunotherapy
Metallo-drugs
Multidrug resistance (MDR)
Peptides as drugs
Pharmacokinetics
Pharmacology
Preclinical studies
Radionuclide therapy
Radiosensitivity and/or resistance
Radiotherapy
Radiotoxicity
Response and/or resistance to therapy
Signal transduction inhibitors
Small molecule inhibitors
Surgery
Target therapy
Viruses
Adenovirus
AIDS/HIV/Kaposi
Epstein-Barr Virus (EBV)
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Herpes virus
Human Papilloma Virus (HPV)
Lentivirus
Oncogenic virus/Viral oncology
Virology